A study published in the highly respected New England Journal of Medicine shows that palliative care, which helps manage symptoms and control pain, is a very effective addition to standard cancer treatment for people with metastatic non-small-cell lung cancer
The Wall Street Journal, March 9, 2016. Patient-safety advocates, including the National Center for Health Research, warn that the bills would weaken the FDA’s ability to ensure devices’ safety.
InsideHealthPolicy.com, March 7, 2016. While minority, patient and consumer groups pushed for more diversity in the clinical trial phase, Jocelyn Ulrich director of scientific and regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), said matching demographic subgroups based on sex, age and race, specifically the African American and Hispanic populations, to disease prevalence would extend phase III clinical trials by 20 months or longer.
If he were playing it safe, Dr. Vinay Prasad might be among the last to turn into a medical provocateur. Prasad’s outspokenness and willingness to criticize industrywide assumptions place him in the ranks of a small but influential group of physicians and researchers who are either having an impact on the way medicine is practiced in the United States, or tilting at windmills.
These are the materials from the Senate briefing we hosted on March 4, 2016 with the Patient, Consumer, and Public Health Coalition titled “Innovation for Healthier Americans: The Impact of Proposed Health Bills on Patients & Consumers”.